Micro-Coring® for the Treatment of Skin Laxity of the Knees

Cytrellis

Status

Invitation-only

Conditions

Knees

Body

Treatments

Device: Micro-Coring

Study type

Interventional

Funder types

Industry

Identifiers

NCT07409090

TP-00460

Details and patient eligibility

About

Early, informal clinical experience suggests that Micro-Coring may help improve skin quality in certain body areas, such as the knees. However, this body region has not yet been formally studied. Additional clinical evaluation is needed to better understand healing, potential side effects, patient experience, ease of use, and optimal treatment settings for body sites. This is especially important because body skin differs from facial skin in thickness, blood supply, movement, and mechanical stress, which may affect both safety and healing outcomes.

Enrollment

12 estimated patients

Sex

All

Ages

22 to 70 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Male or female age 22 to 70
With lax skin over one or both knees, physician discretion
Able to provide written informed consent, understand and willing to comply with all study related procedures and follow-up visits
Fitzpatrick Skin Type I to VI as evaluated by the Investigator

Exclusion criteria

Pregnant women or nursing mothers
Body mass index > 30 · Patients with dermatosis, open wounds, sores, or irritated skin in the treatment area
Patients with allergy to stainless steel or to topical, oral, or injected medications or preparations that may be used during the procedure, such as petrolatum, lidocaine, bupivacaine, chlorhexidine, or povidone-iodine
Patients with a history or presence of any clinically significant bleeding disorder
Patients with dermatological or autoimmune conditions that may affect the treatment outcome; these may include, but are not limited to: actinic keratosis, raised nevi, rosacea, melasma, active acne, cutaneous papules/nodules, active inflammatory lesions, dermatitis, psoriasis, cellulitis, urticarial folliculitis, acute inflammatory phase of scleroderma, rheumatoid arthritis, eczema, psoriasis, allergic dermatitis, collagen disorders, or lupus
Patients with systemic infections or acute local skin infections (as Hepatitis disorders type A, B, C, D, E or F or HIV infection)
Patients who are on a high dose of anti-coagulants or blood-thinning substances, e.g., aspirin > 150 mg/day, nonsteroidal anti-inflammatory drugs (NSAIDs), warfarin, heparin, acetylsalicylic acid during the previous fourteen (14) days
Patients who are on courses of chemotherapy, high-dose corticosteroid use, or radiation in the treatment area
Patients with have undergone surgery of the treatment area within last twelve (12) months, or have any scars less than twelve (12) months old in the treatment area
Patients who have undergone injections of dermal fillers, fat, or botulinum toxin, as well as any minimally invasive/invasive skin treatment in the treatment area during the previous six (6) months
During the study time frame, unwilling to refrain from receiving these following aesthetic treatments within the same body region: toxin, filler, any skin resurfacing (laser, RF, ultrasound, microneedling, etc.);
Are currently enrolled in, or have overlapping participation in, another clinical trial outside of Cytrellis that includes treatment to the study area.
Unwilling to have photography taken for the study purpose
Any physical or psychological factors, in the judgment of the study investigator, may prevent subject from adhering to the study requirement correctly.
History of keloid formation or hypertrophic scarring
Excessive sun exposure and use of tanning beds or tanning creams within 30 days prior to treatment and for the duration of the study